eISSN: 2345-6558

Free Access

Journal of Parathyroid Disease 2017;5(1):17-24
Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients

Original

Usman Kahlid Cheema 1, Armughan Ahmed 2, Chaudhary Muhammad Junaid Nazar 1 * , Ghias Uddin Butt 2, Aftab Cheema 3, Muhammad Bilal 3, Aisha Ashraf 3

1 Department of Nephrology and Renal Transplantation, Shifa International Hospital, Islamabad, Pakistan
2 Department of Nephrology, Pakistan Institute of Medical Sciences, Islamabad, Pakistan
3 Department of Medicine, Shifa International Hospital, Islamabad, Pakistan


*Corresponding author: Chaudhary Muhammad Junaid Nazar,
Email: dr.cmjnazar@live.co.uk


Abstract

Introduction: Hyperphosphatemia is also known as a silent killer among patients with renal failure.

Objectives: The objectives of this investigation was to assess the efficiency and tolerability of sevelamer in hyperphosphatemia in Pakistani patients on regular hemodialysis.

Patients and Methods: A total of 59 dialysis individuals (age >18 years), from both genders, on regular hemodialysis with phosphate level more than 5.5 mg/dL, not on any phosphate binders was enrolled to the study. All the patients received sevelamer 400 mg orally in a dose depending on their baseline serum phosphorus level. Patients received the treatment for duration of 8 weeks. All the patients were followed and investigated for the efficacy and safety variables on fortnightly basis.

Results: The mean (± SD) age of all the enrolled patients was 42.2 (±6.4) years. The mean (±SD) serum phosphorus was reduced significantly to 6.70 (±0.86) mg/dL, 6.00 (±0.64) mg/dL, 5.30 (±0.87) mg/dL and 4.97 (±0.91) mg/dL on day 15 (P < 0.0001), 30 (P < 0.0001), 45 (P < 0.0001) and day 60 (P < 0.0001) respectively. The mean (SD) serum total cholesterol was also reduced non-significantly to 193.9 (±15.6) mg/dL, significantly to 192.1 (±15.9) mg/dL, to 190.6 (±17.0) mg/dL and to 188.1 (±16.3) mg/dL on day 15 (P = 0.085), day 30 (P = 0.003), day 45 (P < 0.0001), and on day 60 (P < 0.0001) respectively.

Conclusion: Our study showed a significant reduction in mean serum phosphorus and total cholesterol, in patients on hemodialysis. Therefore, sevelamer is a safe drug for the treatment of hyperphosphatemia in our clinical settings.



Notes
Please cite this paper as: Cheema UK, Ahmed A, Nazar CMJ, Butt GU, Cheema A, Bilal M, et al. Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients. J Parathyr Dis. 2017;5(1):17-24.

Comments
First name  
Last name  
Email address  
Comments  
Security code



Article
PDF


Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks

Cite by
Google Scholar

Google Scholar
Articles by Usman Kahlid Cheema
Articles by Armughan Ahmed
Articles by Chaudhary Muhammad Junaid Nazar
Articles by Ghias Uddin Butt
Articles by Aftab Cheema
Articles by Muhammad Bilal
Articles by Aisha Ashraf
Similar articles
Related articles

PubMed
Articles by Usman Kahlid Cheema
Articles by Armughan Ahmed
Articles by Chaudhary Muhammad Junaid Nazar
Articles by Ghias Uddin Butt
Articles by Aftab Cheema
Articles by Muhammad Bilal
Articles by Aisha Ashraf


Article Access Statistics
Viewed
PDF Downloaded
Comments

Share this article!
Creative Commons Attribution 4.0 License This work is licensed under a Creative Commons Attribution 4.0 License.
Copyright © 2016 The Author(s)
Published by Nickan Research Institute